⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94571 | 1.00 | — | — | |
| SCHEMBL1872941 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2011967 | 0.97 | — | — | |
| SCHEMBL31048379 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL4328612 | 0.97 | — | — | |
| SCHEMBL5482526 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2011971 | 0.97 | — | — | |
| Bromide SCHEMBL11156909 | 0.97 | — | — | |
| SCHEMBL31350235 | 0.97 | CYP2D6 (0.52) | — | |
| Hydrochloric Acid SCHEMBL31323394 | 0.95 | KMT2A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4695262-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4126832-B1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250250287-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE SWITZERLAND GMBH (CH) | 2025-08-07 | — | — | US | disclosed |
| EP-4587124-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | Enliven Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-1471060-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6528504-B2 | Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. | AJINOMOTO CO., INC. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | AJINOMOTO CO., INC. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1142884-A1 | OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| EP-0404359-B1 | Dibenzothiazepine derivatives useful as antispasmodic agents | PFIZER LTD (GB) | 1994-06-29 | — | — | EP | disclosed |
| US-5071844-A | Antispasmodic agents | PFIZER INC. (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0404359-A1 | Dibenzothiazepine derivatives useful as antispasmodic agents | Pfizer Limited (GB) | 1990-12-27 | — | — | EP | disclosed |
| CN-1047673-A | Anticonvulsants | PFIZER (US) | 1990-12-12 | — | — | CN | disclosed |